Lunit

What Lunit does

Lunit is a South Korea-based, publicly listed (KOSDAQ:328130) medical AI company founded in 2013 that develops and commercializes deep-learning software for cancer screening and precision oncology. Its portfolio is organized around two product families — Lunit INSIGHT for radiology (2D/3D mammography, chest X-ray, image-based 5-year breast cancer risk) and Lunit SCOPE for pathology (tumor-microenvironment analysis, HER2/PD-L1/universal IHC quantification, H&E-based genotype prediction) — underpinned by proprietary multimodal medical foundation models trained on approximately 1.2 million globally diverse images and exposed operationally through a Foundation Model Services platform for custom enterprise fine-tuning. Lunit reports deployment at more than 10,000 customer sites across 65+ countries, with regulatory clearances spanning FDA 510(k), EU MDR/IVDR CE mark, Korean MFDS approval, ISO 13485, MDSAP, and ISO 27001 in 56+ jurisdictions.

Lunit monetizes the platform through three concurrent revenue streams: (1) recurring enterprise software licensing of Lunit INSIGHT and the acquired Volpara breast-imaging suite (Scorecard, Risk Pathways, Analytics, Live, Patient Hub) to hospitals, imaging networks, teleradiology providers and public screening programs via multi-year contracts (e.g., a 5-year SEHA contract covering 14 hospitals and 70+ clinics with 100,000+ mammography images; SimonMed Imaging across 175+ US sites); (2) biopharma precision-oncology services using Lunit SCOPE for biomarker discovery, IHC quantification, immunotherapy-response prediction and companion-diagnostic development, with named partners including Daiichi Sankyo, AstraZeneca, Agilent, CellCarta, Labcorp and Myriad Genetics; and (3) managed-services / Foundation Model Services engagements that build custom enterprise models (e.g., SimonMed chest X-ray report generation). Distribution combines direct enterprise sales through four regional subsidiaries (Americas, USA, Japan, Europe) with deep OEM and platform integrations across Fujifilm, GE Healthcare, Philips, AGFA, Infinitt, Samsung, Leica Biosystems, Indica Labs, Microsoft Azure and Dragon Copilot, plus listings on Harrison.ai's Open Platform, deepc, CARPL and Leica's Aperio AI Store.

The company's growth has been financed by a $150M KOSDAQ public capital increase (Nov 2023), a ₩166.5B convertible-bond issuance funding the May 2024 Volpara Health Technologies acquisition (~$193M), a subsequent ₩211B rights offering completed April 2026 for debt repayment and operating capital, and the September 2025 acquisition of Prognosia Breast. With reported revenue scaling from a 2021 base of ~₩5.6B (KRW) to ~₩57.6B in 2025 — a roughly tenfold increase over four years alongside substantial EBITDA losses — Lunit has set an explicit path-to-profitability target of 2027 and is positioning Foundation Model Services, the Volpara channel, and the biopharma companion-diagnostic pipeline as the principal monetization vectors beyond traditional enterprise screening licensing.

Name

Lunit

Legal name

Lunit Inc.

Website

https://lunit.io

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

Lunit is a South Korean public medical AI company (KOSDAQ:328130) selling AI-powered cancer screening (Lunit INSIGHT) and precision-oncology (Lunit SCOPE) software to hospitals, imaging networks, biopharma companies and national screening programs across 65+ countries.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Software Publishers (5132), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Medical imaging AI
• Cancer screening software
• Precision oncology AI
• Digital pathology AI
• Radiology AI platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Enterprise software licensing (Cancer Screening): Recurring software licensing of Lunit INSIGHT MMG/DBT/CXR and Volpara breast-imaging suite to hospitals, imaging networks and teleradiology providers, sold via enterprise contracts and channel integrations (e.g., 5-year SEHA contract, multi-year SimonMed deployment).
2. Biopharma precision-oncology / companion diagnostics services: Paid collaborations with global pharma (Daiichi Sankyo, AstraZeneca, Agilent, CellCarta, Labcorp) for biomarker discovery, translational research, and clinical-trial patient stratification using Lunit SCOPE. Revenue from research partnerships and CDx development programs.
3. Foundation Model Services / custom model deployment: Custom fine-tuning of multimodal foundation models on customer imaging data (e.g., SimonMed chest X-ray report generation), generating project-based and enterprise deployment revenue.
4. Capital markets financing (equity / convertible bonds): Recurring capital raised via primary equity issuances (e.g., 2023 $150M capital increase, 2026 ₩26,750 per-share rights offering) and 2024 ₩166.5B convertible bond issuance used to fund the Volpara acquisition and global expansion.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Core offering

Lunit develops and sells medical AI software that converts medical imaging and pathology data into clinical insights for cancer detection and treatment. Its portfolio covers cancer screening (Lunit INSIGHT MMG, DBT, CXR, and image-based Risk), precision oncology biomarker analysis (Lunit SCOPE IO, IHC Suite, GP, PD-L1 CAL10), mammography workflow management (the Volpara suite and Patient Hub), and a foundation-model platform that lets customers fine-tune custom multimodal medical AI. Products are sold as regulated software (FDA 510(k), CE, MFDS) to hospitals, imaging networks, biopharma companies, and public screening programs, and are embedded into OEM imaging/PACS/digital-pathology platforms.

Product overview

Lunit operates a platform-plus-modules architecture split across two clinical product lines — Radiology AI (Lunit INSIGHT family) and Precision Oncology (Lunit SCOPE family) — augmented by the Volpara suite acquired to extend mammography quality and risk offerings. The core platform backbone is Lunit's medical multimodal foundation model stack, exposed operationally through Foundation Model Services and underpinning predictive products such as Lunit INSIGHT Risk (image-based breast cancer risk prediction), Lunit SCOPE GP (genotype prediction from H&E), and Lunit SCOPE IO (tumor microenvironment analysis). On the detection side, the Lunit INSIGHT family includes Lunit INSIGHT MMG (2D mammography AI), Lunit INSIGHT DBT (3D mammography AI), and Lunit INSIGHT CXR (chest X-ray AI), with chest X-ray report generation extending into Microsoft Dragon Copilot. The Lunit SCOPE family is an IHC and pathology platform whose SCOPE IHC Suite bundles SCOPE uIHC (universal IHC quantification), SCOPE HER2 (breast HER2 scoring), and SCOPE PD-L1 (Clone 22C3, CE marked), with SCOPE PD-L1 CAL10 (Clone CAL10 for NSCLC) joining in May 2026. Acquired Volpara modules (Scorecard, Risk Pathways, Analytics, Live) and Patient Hub add density assessment, real-time quality control, risk-pathway navigation, and patient-facing reporting around the mammography workflow.

Differentiator

Problem solved

Functional benefit

Brands

• Lunit INSIGHT MMG: 2D mammography AI for breast cancer detection
• Lunit INSIGHT DBT
• Lunit INSIGHT CXR
• Lunit INSIGHT Risk
• Lunit SCOPE IO
• Lunit SCOPE HER2
• Lunit SCOPE PD-L1
• Lunit SCOPE uIHC
• Lunit SCOPE GP
• Volpara Scorecard
• Volpara Analytics
• Volpara Live
• Volpara Risk Pathways
• Patient Hub

Products and services

• Lunit INSIGHT MMG AI software for 2D mammography that detects and localizes suspicious breast lesions, outputting abnormality scores and heatmaps to assist radiologist reading; FDA 510(k) cleared and CE marked. Used by hospitals, imaging networks, and teleradiology providers for breast cancer screening.
• Lunit INSIGHT DBT AI software for 3D mammography (digital breast tomosynthesis) that detects and characterizes lesions across DBT slices to support breast cancer screening, with current-prior comparison in v1.2; FDA 510(k) cleared and CE marked.
• Lunit INSIGHT CXR AI software for chest X-ray that detects 10+ abnormal findings (e.g., pulmonary nodule, pneumothorax, pleural effusion) and outputs location and abnormality scores; CE marked and EU MDR certified, integrated with Microsoft Dragon Copilot for report generation.
• Lunit INSIGHT Risk Image-based breast cancer risk prediction model that estimates a patient's 5-year invasive breast cancer risk directly from mammography images, designed to support personalized risk-based screening; FDA Breakthrough Device designation.
• Volpara Scorecard Volumetric breast density assessment and quality assurance tool providing standardized BI-RADS density categories and mammography quality metrics for screening programs.
• Volpara Risk Pathways Risk assessment and patient management pathway software that integrates breast cancer risk models with screening workflow recommendations and follow-up scheduling.
• Volpara Analytics Mammography quality management analytics platform providing facility-, technologist-, and reader-level performance dashboards.
• Volpara Live Real-time mammography quality management tool that provides technologists immediate feedback on image quality at the point of acquisition.
• Patient Hub Patient-facing mammography reporting and communication module that generates personalized lay-language screening reports for women undergoing breast exams.
• Lunit SCOPE IO AI pathology analyzer that quantifies tumor-infiltrating lymphocytes and tumor cellularity on H&E slides to characterize the tumor microenvironment and support immunotherapy decisions.
• Lunit SCOPE IHC Suite Suite of AI-powered IHC quantification modules covering HER2, PD-L1 (Clone 22C3, CE marked), and universal IHC quantification for pathology labs, pharmaceutical research, and companion-diagnostic development.
• Lunit SCOPE PD-L1 CAL10 AI-powered PD-L1 (Clone CAL10) biomarker analysis for non-small cell lung cancer, integrated with Leica Biosystems Aperio GT 450 scanners and Indica Labs HALO AP image management, available through the Leica Aperio AI Store.
• Lunit SCOPE GP Genotype prediction AI that infers molecular biomarkers and gene mutation status (e.g., EGFR, KRAS, MSI) directly from H&E pathology images using Lunit's multimodal foundation models, enabling virtual genomic testing.
• Lunit Foundation Model Services Medical multimodal foundation-model platform that allows enterprise customers to fine-tune and deploy custom medical AI models on their own imaging data in HIPAA-compliant environments, available as a service offering.

Quantifiable outcome

• More than 330 breast-imaging sites in the Americas supporting ~1 million screening mammograms annually (April 2026)
• +8 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability11 records

Feature9 records

Partnerships

29 partnerships are on record, tiered flagship, core and minor.

• MicrosoftflagshipStrategic or Co-development PartnerMulti-year strategic collaboration to co-develop cloud-based clinical AI solutions on Microsoft Azure, enabling customization of Lunit models (SCOPE HER2, INSIGHT DBT) with site-specific clinical data. Integration with Microsoft's agentic AI frameworks for workflow automation. Listed as one of Lunit's top-tier global partners on the About-Us timeline.
• Leica BiosystemsflagshipStrategic or Co-development PartnerCo-developed and launched Lunit SCOPE PD-L1 CAL10, the first product from a March 2026 digital-pathology collaboration, optimized for Leica's PD-L1 antibody CAL10 and Aperio GT 450 scanner. Available through Leica's Aperio AI Store; Lunit SCOPE HER2 and other IHC algorithms co-marketed.
• Indica LabscoreTechnology or IntegrationThree-way collaboration with Leica Biosystems to integrate Lunit's SCOPE algorithm into the Aperio HALO AP image-management workflow for digital pathology, providing standardized PD-L1 and other biomarker scoring across sites.
• Agilent TechnologiesflagshipStrategic or Co-development PartnerNon-exclusive collaboration to co-develop AI-powered companion-diagnostic solutions combining Lunit's AI algorithms with Agilent's tissue-based diagnostics. Initial focus on co-developed AI-powered assays for research and clinical trials; presented joint c-MET/NSCLC study at AACR 2026.
• Daiichi SankyoflagshipStrategic or Co-development PartnerCollaboration to integrate Lunit SCOPE (uIHC, IO) into two of Daiichi Sankyo's oncology pipeline programs for biomarker discovery, immune phenotyping, and improved patient stratification in clinical trials. Marked as Daiichi Sankyo's first introduction of AI into new-drug development.
• AstraZenecaflagshipStrategic or Co-development PartnerPartnership to develop AI-driven biomarker prediction tools and collaborate on AI-powered oncology research (per Genomeweb Nov 2024). Lunit listed as part of AstraZeneca's AI oncology network on the About-Us timeline.
• LabcorpflagshipStrategic or Co-development PartnerStrategic collaboration to advance AI-powered digital pathology research in oncology, with published studies identifying immune-active NSCLC subtypes; expansion planned to additional cancer types. Includes share-repurchase and pTau181 blood-test commercial roadmap.
• CellCartaflagshipStrategic or Co-development PartnerStrategic collaboration announced March 30, 2026 to accelerate AI-enabled digital pathology workflows for biopharma companion-diagnostic programs. Combines Lunit's platform-agnostic AI with CellCarta's global CDx and laboratory infrastructure, starting with pilot opportunities.
• SimonMed ImagingflagshipStrategic or Co-development PartnerMulti-year strategic partnership to deploy one of the first large-scale custom foundation models for chest X-ray report generation across SimonMed's 175+ US locations, using Lunit's Foundation Model Services in a HIPAA-compliant environment. Plans to expand to mammography and DBT in 2026.
• FujifilmcoreStrategic or Co-development PartnerLong-term imaging and AI partner; jointly developed CXR-AID which received PMDA approval in Japan. Fujifilm is also a PACS/imaging integration partner. Early-stage Series B-1 investor ($5M).
• GE HealthcarecoreTechnology or IntegrationImaging-vendor integration partner for Lunit AI into GE Healthcare's PACS and imaging stack, enabling joint deployments in customer hospitals.
• PhilipscoreTechnology or IntegrationImaging-vendor integration partner for Lunit AI into Philips PACS/imaging environments. Listed on About-Us timeline as a key partner.
• AGFAcoreTechnology or IntegrationImaging-vendor integration partner; Lunit AI is integrated into AGFA imaging platforms to streamline radiology workflows.
• Infinitt HealthcarecoreTechnology or IntegrationPACS/imaging integration partner for Lunit INSIGHT products in clinical environments.
• Myriad GeneticscoreStrategic or Co-development PartnerDiagnostics partner for companion-diagnostic and precision-oncology programs, integrating Lunit SCOPE with Myriad's genetic testing portfolio.
• Harrison.aicoreChannel Partner/ Reseller/ DistributorLunit joined Harrison.ai's Open Platform ecosystem alongside AIRAmed, Koios Medical and Nanox AI, providing vendor-neutral PACS/RIS/EHR integration with zero mark-up. Distribution across 1,000+ Harrison.ai customer sites including 40+ NHS Trusts and all Hong Kong public emergency departments.
• SOFT LANDERSminorOthersLunit is among 250+ corporate clients (including NAVER, KOGAS, KT, SK hynix) using SOFT LANDERS' global corporate-payment platform for expatriate-expense management across 50+ countries.
• National Cancer Institute (NCI, US)coreStrategic or Co-development PartnerResearch partnership listed on Lunit's About-Us timeline for advancing AI in oncology.
• KAIST (Korea Advanced Institute of Science and Technology)coreStrategic or Co-development PartnerResearch collaboration with KAIST under the Lunit consortium, including medical-AI projects for ER triage and drug-candidate structure prediction; 94% accuracy demonstrated in interim evaluation.
• Yonsei University Severance HospitalcoreStrategic or Co-development PartnerMOU signed May 14, 2026 to jointly develop, validate, and commercialize medical-AI applications built on a medical-science foundation model, drawing on Severance's clinical data and Lunit's AI capabilities. Co-authored HER2+ BTC trial presented at ASCO 2026.
• Seoul National University HospitalminorStrategic or Co-development PartnerJoint research using Lunit SCOPE IO on adenoid cystic carcinoma (ACC) tumor-microenvironment analysis, presented at ASCO 2026.
• Asan Medical CenterminorStrategic or Co-development PartnerJoint research on AI-powered TME analysis in MSS metastatic colorectal cancer, presented at ASCO 2026.
• Ajou University Medical CenterminorStrategic or Co-development PartnerCo-authored study with Agilent Technologies using Lunit SCOPE IO and uIHC to analyze 25,000+ NSCLC samples for c-MET expression and tumor microenvironment, presented at AACR 2026.
• Yale University School of Medicine (Dr. David Rimm's lab)minorStrategic or Co-development PartnerJoint AI-based analysis of tumor-infiltrating lymphocytes in NSCLC and association with immunotherapy response, presented at AACR 2026.
• SEHA (Abu Dhabi Health Services Company)flagshipStrategic or Co-development PartnerFive-year contract (March 2025) to deploy Lunit INSIGHT MMG across SEHA's 14 hospitals and 70+ clinics, expected to analyze more than 100,000 mammography images; first major national AI breast-screening program in the Middle East.
• Valencian Community (Spain)coreOthersSelected as exclusive AI partner for Spain's Valencian Community breast-screening program.
• 11 Italian Regional Health AuthoritiescoreOthersSupply agreement with 11 Italian regional health authorities for Lunit's AI cancer-diagnostic solutions (announced August 2025).
• Volpara Health Technologies (New Zealand)flagshipStrategic or Co-development PartnerAcquired by Lunit in 2024 for approximately $193M (₩166.5B in convertible bonds). Now operates under the Lunit brand, expanding Lunit's breast-imaging AI ecosystem to 330+ Americas sites and 1M+ annual mammograms.
• Prognosia Breast (Washington University spinout)coreStrategic or Co-development PartnerAcquired by Lunit a few months after Prognosia Breast received FDA Breakthrough Device designation in June 2025; now powers Lunit INSIGHT Risk with a 5-year breast cancer risk model (AUC 0.80, capturing ~60% of 5-year cancers in ~16% of women).

Scale indicators14 records

Recent moves10 records

Expansion highlights8 records

Direct peers

• iCAD, Inc. iCAD offers ProFound AI for 2D mammography and DBT, the most direct global competitor to Lunit INSIGHT MMG/DBT, with FDA-cleared breast-screening AI sold to the same hospital and imaging-center customers.
• ScreenPoint Medical: ScreenPoint's Transpara mammography AI competes head-to-head with Lunit INSIGHT MMG and DBT, and has been validated in head-to-head studies (e.g., MASAI) using the same evidence-heavy approach Lunit employs.
• Therapixel: Therapixel's MammoScreen 2.x is an FDA-cleared and CE-marked mammography AI directly comparable to Lunit INSIGHT MMG, with both vendors competing for breast-screening program contracts in Europe and the US.
• Paige AI: Paige is a leading digital pathology AI company with FDA-authorized prostate cancer detection and biomarker products, directly comparable to Lunit SCOPE in the pathology and biopharma CDx market.
• Ibex Medical Analytics: Ibex's Galen platform provides AI-powered cancer detection and biomarker quantification on H&E and IHC slides, overlapping directly with Lunit SCOPE IO, HER2 and PD-L1 products in pathology labs.
• Proscia: Proscia provides Concentriq and AI pathology applications for biomarker quantification, competing with Lunit SCOPE in both biopharma research and clinical pathology workflows.
• Qure.ai: Qure.ai offers FDA-cleared chest X-ray, CT and head-CT AI (qXR, qER) overlapping with Lunit INSIGHT CXR and competing for the same radiology-AI customer base across emerging and developed markets.
• Aidoc: Aidoc is a leading enterprise radiology-AI platform spanning CT, X-ray and MRI triage, often competing with Lunit INSIGHT in large hospital networks and imaging-center deployments.

Broad incumbents

• Hologic, Inc. Hologic is the dominant mammography hardware vendor (3Dimensions, Selenia) and sells Genius AI detection software, competing with Lunit both as a scanner/PACS provider and as an embedded AI alternative to Lunit INSIGHT.

Emerging players

• DeepHealth (RadNet subsidiary): DeepHealth (acquired by RadNet) is building an integrated AI and imaging-operations stack, including mammography and prostate AI, positioning it as both a partner and competitor to Lunit in screening AI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Lunit_AI
• LinkedInlinkedin.com/company/lunit

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds11 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lunit